DeltaHealth China

deltahealth.com.cn

DeltaHealth is an innovative healthcare provider primarily invested by Eight Roads and its affiliate Eight Roads Ventures China. As of now, it is also the first and the only medical institution with a consultation and advisory relationship with Columbia HeartSource in China. DeltaHealth is committed to establishing an integrated network of hospitals and clinics in China that specializes in cardiovascular care and always puts patients first. We aim to bring to our patients a set of innovative and personalized medical services. To achieve this, we are building on some of the great medical management practices in the West while combining the world's excellent physicians and state-of-the-art medical technology under one roof. In addition to providing diverse and high-quality healthcare services, we also strive to improve the diagnosis and treatment of cardiovascular diseases, and deliver better experience for patients. We see this as our contribution to the development of the medical system in China.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Pharmacy Market

ALNYLAM ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR OXLUMO® (LUMASIRAN) IN ADVANCED PRIMARY HYPEROXALURIA TYPE 1

Alnylam Pharmaceuticals, Inc. | October 07, 2022

news image

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration approved a label expansion for OXLUMO® an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients. The approval is based on positive efficacy and safety results of the ILLUMINATE-C Phase 3 study of OXLUMO in patients wi...

Read More

Business Insights, PHARMACY MARKET

MEDINCELL’S PARTNER TEVA ANNOUNCES SUCCESSFUL LAUNCH OF UZEDY™

Businesswire | August 03, 2023

news image

MedinCell During today’s Q2 earnings call, Richard Francis, President and CEO of Teva, and Eric Hughes, Executive Vice President, Global R&D & Chief Medical Officer, commented the US launch of UZEDY since May 2023 and the olanzapine Long-Acting Injectable (LAI). About UZEDY Richard Francis said1 “We are actually right on plan or slightly ahead of our market access strategy targets and we are very happy with the launch.&r...

Read More

Business Insights

TITAN PHARMACEUTICALS ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT AND PIPE OFFERING PRICED AT-THE-MARKET

Titan Pharmaceuticals, Inc. | February 03, 2022

news image

Titan Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering. In addition, the C...

Read More

Business Insights

INDEGENE PARTNERS WITH AMWELL TO EMPOWER LIFE SCIENCES ORGANIZATIONS WITH UNPARALLELED PATIENT SUPPORT SOLUTIONS

Indegene Inc | June 29, 2022

news image

Indegene, a technology-led healthcare solutions provider, announced a partnership with Amwell®, a digital care delivery leader. This collaboration will facilitate life sciences organizations to connect patients to better quality care and drive better health outcomes. Digital patient engagement has disrupted the healthcare landscape. Patients are increasingly becoming more knowledgeable and involved in their health journeys. They want personalized support solutions that are ava...

Read More
news image

Pharmacy Market

ALNYLAM ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR OXLUMO® (LUMASIRAN) IN ADVANCED PRIMARY HYPEROXALURIA TYPE 1

Alnylam Pharmaceuticals, Inc. | October 07, 2022

Alnylam Pharmaceuticals, Inc. the leading RNAi therapeutics company, announced that the U.S. Food and Drug Administration approved a label expansion for OXLUMO® an RNAi therapeutic administered via subcutaneous injection, now indicated for the treatment of primary hyperoxaluria type 1 to lower urinary oxalate and plasma oxalate levels in pediatric and adult patients. The approval is based on positive efficacy and safety results of the ILLUMINATE-C Phase 3 study of OXLUMO in patients wi...

Read More
news image

Business Insights, PHARMACY MARKET

MEDINCELL’S PARTNER TEVA ANNOUNCES SUCCESSFUL LAUNCH OF UZEDY™

Businesswire | August 03, 2023

MedinCell During today’s Q2 earnings call, Richard Francis, President and CEO of Teva, and Eric Hughes, Executive Vice President, Global R&D & Chief Medical Officer, commented the US launch of UZEDY since May 2023 and the olanzapine Long-Acting Injectable (LAI). About UZEDY Richard Francis said1 “We are actually right on plan or slightly ahead of our market access strategy targets and we are very happy with the launch.&r...

Read More
news image

Business Insights

TITAN PHARMACEUTICALS ANNOUNCES PRICING OF $5.5 MILLION REGISTERED DIRECT AND PIPE OFFERING PRICED AT-THE-MARKET

Titan Pharmaceuticals, Inc. | February 03, 2022

Titan Pharmaceuticals, Inc. announced that it has entered into a securities purchase agreement with a single institutional investor to purchase 3,374,242 shares of its common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, Titan has also agreed to issue and sell to the investor 1,289,796 pre-funded warrants, at the same purchase price as in the registered direct offering. In addition, the C...

Read More
news image

Business Insights

INDEGENE PARTNERS WITH AMWELL TO EMPOWER LIFE SCIENCES ORGANIZATIONS WITH UNPARALLELED PATIENT SUPPORT SOLUTIONS

Indegene Inc | June 29, 2022

Indegene, a technology-led healthcare solutions provider, announced a partnership with Amwell®, a digital care delivery leader. This collaboration will facilitate life sciences organizations to connect patients to better quality care and drive better health outcomes. Digital patient engagement has disrupted the healthcare landscape. Patients are increasingly becoming more knowledgeable and involved in their health journeys. They want personalized support solutions that are ava...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us